FAPI-PET/CT imaging for diagnosing and staging pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective Phase 2/3 diagnostic study will image adults with suspected primary or recurrent pancreatic cancer using the 18F‑FAPI‑74 PET/CT tracer. Participants undergo whole‑body PET/CT at the Turku PET Centre and the FAPI findings will be compared against conventional imaging (triphasic CT and, when available, 18F‑FDG PET/CT) and clinical or pathological reference standards. The main aims are to determine patient‑level sensitivity and specificity for detecting local lymph node metastasis and distant metastasis in initial staging and suspected recurrence. Eligible patients are aged 18–85 with WHO performance status 0–2 and must be able to provide informed consent.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Suspected primary or recurrent pancreatic cancer
* Subjects must be male or female aged 18-85 years.
* WHO performance score 0-2.
* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.

Exclusion Criteria:

* Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.
* Study subject is not able to understand the purpose of the study.
* Medical conditions prohibiting whole-body PET/CT imaging.

Where it's running

• Turku PET Centre, Turku University Hospital
  Turku, Finland Recruiting

Study contacts

• Principal investigator: Saila Kauhanen, docent — University of Turku and Turku University Hospital
• Study coordinator: Saila Kauhanen, docent
• Email: saila.kauhanen@utu.fi
• Phone: +358503017010

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)

  This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.

  Recruiting Phase 1 Matter Bio, Inc. · The Bronx, New York · NCT07828236

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.